Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
AssigneesUniversity of Pennsylvania, The Children's Hospital of Philadelphia
InventorsAlan M. Gewirtz, Mortimer Poncz
Life of this patent
Estimating the term…
Abstract
Neutrophil activating peptide-2 or analog thereof is administered to a mammal to achieve therapeutic reduction of the number of circulating platelets. The peptide is useful in treating essential thrombocythemia and reactive thrombocytosis.
Claims6
A method for reducing the number of circulating platelets in the bloodstream of a mammal comprising administering to the mammal an amount of neutrophil activating peptide-2 effective to induce such a reduction.
A method for reducing the number of circulating platelets in the bloodstream of a mammal comprising administering to the mammal a platelet number-reducing effective amount of a conjugate comprising neutrophil-activating peptide-2 operatively linked to a pharmaceutically acceptable carrier molecule.
Dependencies are inferred from the claim text.